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An underlying assumption of quality of life outcome research is that after some intervention a “steady-state” of quality of life
is reached which can be identiﬁed as an endpoint, and, hence, the “outcome.” However, in some disease processes, no so such
steady-state is reached. The hypothesis presented is that a disease process with a waxing and waning course will make it diﬃcult
to determine a quality of life endpoint. After clinical observation, a pilot study of patients with either diabetic or idiopathic
gastroparesis with gastric neurostimulation their records were reviewed to identify the number of clinic visits, the number of clinic
visits in which the patients were asymptomatic, much improved, improved, no change, worse, or much worse. These changes were
deﬁned as “transitions.” A “transition ratio” was calculated by dividing the number of transitions by the number of clinic visits.
Preliminary results showed that of 32 patients, the median number of clinic encounters was 8 (1–35), and the median number of
transitions 4 (0–22). The average transition ration was 0.56 ± 0.31. In the case of gastroparesis, over half of all clinical encounters
were associated with a transition. The implication of the hypothesis and preliminary ﬁnding suggests a diﬃculty to identify when
the symptomatic endpoint was reached. Other methods to assess the eﬀects of treatment in such a disease process are required to
fully understand the eﬀects of treatment on quality of life.
Copyright © 2009 Vic Velanovich. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The purpose of quality of life research is to explore the
eﬀects of disease and its treatment on a variety of patient-
centered experiences. This is done using a range of methods,
primarily with some type of quality of life instruments. In
clinical medicine, one of the most active areas of research is
related to the quality of life eﬀects of a speciﬁc treatment.
In this setting, the usual study design is to have a group
of patients with the disease of interest complete one or
moreinstrumentsprior totheintervention, thenthepatients
receive the intervention (with or without a comparison
group not receiving the intervention), then at some arbitrary
time, the instrument is readministered [1]. An underlying
assumption, albeit frequently unstated, is that at the point
of post treatment reassessment, the patient has reached the
maximal beneﬁt (or detriment) of the treatment. This can
be thought of as a “steady-state” (Figure 1). Theoretically,
this steady-state is the quality of life outcome of the
intervention.
2.AnHypothesis
In practice, however, identifying this steady-state may be
problematic. In most quality of life studies, quality of life is
assessed at some arbitrary temporal endpoint, say, 3 months,
6 months, 1 year, and so forth, The assumption made by
these researchers is that whatever eﬀect the intervention has
made on quality of life would have been reached by that
time. For many diseases and intervention, this may be true.
However, it is also clear that not all disease processes ﬁt
this model. That is to say, these diseases have a natural
waxing and waning symptomatic and quality of life natural
history. Examples of such diseases are inﬂammatory bowel
disease and rheumatoid arthritis. Therefore, at the point the
instrument is administered (a “good day” or a “bad day”),
will aﬀect the quality of life data obtained. The hypothesis
presented is that in such disease processes which have a
natural history of a waxing and waning symptomatic course,
such an arbitrary endpoint may be misleading as to the





































Figure 1: Hypothetical quality of life measurement after an
operation for a disease. After initial fall in quality of life related to
the operation, as the patient recovers, quality of life will improve to
a level better than the patient’s preoperative status.
of one such disease, gastroparesis [2], and how its natural
symptomatic volatility aﬀects the assessment of the gastric
neurostimulation is presented as a pilot study.
3. Evaluationof the Hypothesis
This study was approved by the institutional review board
of the Health Ford Health System. The Enterra device
(Medtronic, Inc., Minneapolis, Minn, USA) provides electri-
calstimulationtothestomachwiththepurposeofdecreasing
the symptoms of gastroparesis. It is approved for use by the
United States Food and Drug Administration under their
Humanitarian Device Exemption for patients with diabetic
and idiopathic gastroparesis. Patients were followed up every
two to four weeks until maximal symptomatic improvement
was reached, then they were to complete quality of life
instruments.
A retrospective review of all clinical encounters of
post-treatment patients treated for diabetic or idiopathic
gastroparesis was done. The medical record was reviewed
for age, gender, length of followup, and number of post-
treatment clinical encounters. A clinical encounter included
all outpatient visits speciﬁcally related to gastroparesis
or management of the neurostimulator, or an inpatient
hospitalization at which time a consultation was requested
for gastroparesis or management of the neurostimulator.
All patients were followed prospectively and during each
clinical encounter, patients were asked as to their symptoms
of gastroparesis. Patients rated their symptoms as much
worse, worse, no change, improved, much improved, or
asymptomatic. Any change in symptoms, whether improved
or worsened, was deﬁned as a “transition.” The concept
here is that when a steady-state is reached, there will be
few, if any, transitions. A “transition ratio” was calculated
as transition ratio = number of clinical encounters with
a transition/total number of clinical encounters. Both the
concepts of transitions and transition ratio are novel to the
thinking of the natural history of gastroparesis.
In order to have a better understanding of symptomatic
variabilityovertime,plotsofthechangeofsymptomseverity









Figure 2: A gastroparesis patient with a great deal of symptomatic














Figure 3: A patient whose symptoms did not change until clinical
encounter number 8, then worsened, with no change after that.
reported symptom improvement, then his/hers symptom
level rose by 1; if much improved, then by 2; if worsened,
it decreased by 1; much worse, by 2. If a patient reported that
he was asymptomatic, then a score of 10 was given. If the
patient reported no change in symptoms, then the score was
kept at the same level as his/her previous visit.
4.EmpiricalData
A number 32 patients were included in the study: 23 were
female; the mean age of all patients was 42 ± 14 years. The
median followup was 8 months (range: 1–37 months). The
median number of clinical encounters was 8 (range: 1–35).
The median number of clinical transitions was 4 (range: 0–
22). The mean transition ratio was 0.56 ±0.31.
Figures 2 and 3 present individual patients variation in
symptom severity from clinical visit to clinic visit.
5. Implicationsof the Hypothesis
andDiscussion
The implications of this hypothesis and preliminary ﬁndings
is that choosing an arbitrary temporal endpoint in diseases
with variability in symptoms and quality of life may over
or under estimate the overall eﬀect of treatment. The
importance of symptomatic variability lies in determining
when the “outcome” of the treatment is reached. If an
arbitrary temporal endpoint is used, say 1 month, 1 year,
and so forth, then whether the patient is having a “good
day” or a “bad day” will aﬀect how the patient answers theGastroenterology Research and Practice 3
itemsofwhateverinstrumentisused.Therefore,theoutcome
measured at this point may not be fully reﬂective of the
patient experience.
A counter argument is that if the treatment is truly eﬀec-
tive in improving symptoms and quality of life in aggregate,
the summary statistics (mean, median, etc.) should be better
than control subjects’ or the patients’ baseline summary
statistics. It is interesting, though, that in a cross-over trial of
gastric neurostimulation, patients more frequently preferred
the device to be on (i.e., providing electrical stimulation)
than oﬀ, even though the symptom severity score used
showed no statistically signiﬁcant diﬀerence [3]. Although
one of the potential explanations for this ﬁnding is that
the instrument used was not sensitive enough to detect
change in the symptoms important to the patient, the
other explanation is that the variability in symptoms was
so great that the standard error of the mean was to wide
to be of statistical signiﬁcance. Yet, the patients themselves,
over the time period that the device was on, felt that
there was overall improvement despite the symptomatic
variability. Therefore, summary statistics in disease processes
with “natural” variation in symptom severity and quality
of life may show, in statistical terms, a type II error—that
is to say, not accepting that a true diﬀerence exist when
in fact one does [4]. One can easily see this is the case in
gastroparesis with in about one-half of clinical encounters
patients reported either improvement or worsening of their
symptoms from the previous encounter. Even, this statistic
does not accurately reﬂect individual patient symptomatic
variability, as evidence by plotting the change in symptoms
from one clinical encounter to the next for individual
patients (Figures 2 and 3).
Several approaches have been developed to address
longitudinal quality of life data [5]. Examples of these
include analyzing the area of curve, graphical presentations,
tabular presentations, or statistical modeling techniques [5].
Although it is not the purpose of this study to assess the
advantages or disadvantages of each technique, all do require
repeated, multiple administrations of whatever instrument
is used. Obviously, as the number of administrations is
increased, the chance of encountering missing data is also
increased.
In summary, this hypothesis and preliminary results
demonstrate that patients suﬀering from idiopathic or
diabetic gastroparesis have temporally related variability in
their symptoms. Therefore, the choice of when a symptom
severity or quality of life instrument is administer may aﬀect
thatdatathatisobtaineddependingonwhetheritwasagood
day or a bad day for the patient. Such data may not be truly
reﬂective of the patient experience and may lead to aﬀect
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